NP-02

About CNBX Pharmaceuticals

CNBX Pharmaceuticals is a clinical-stage biotech company developing a pipeline of cannabinoid-based drug candidates for cancer and neuropsychiatric disorders. Its core asset, RCC-33, is positioned as a first-in-class candidate for colorectal cancer, currently in late preclinical stages preparing for an IND. The company utilizes an in-house drug discovery platform centered on high-throughput screening of cannabinoid formulations against various cancer types. Leadership combines business acumen with scientific and clinical expertise, supported by a notable advisory board in oncology.

Therapeutic Areas

Other Neuropsychiatry (unspecified) Drugs